BGNE - BeiGene, Ltd.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
143.28
+1.97 (+1.39%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close141.31
Open141.86
Bid135.00 x 1400
Ask159.90 x 800
Day's Range140.32 - 143.64
52 Week Range105.19 - 220.10
Volume273,953
Avg. Volume654,109
Market Cap8.516B
Beta (3Y Monthly)1.73
PE Ratio (TTM)N/A
EPS (TTM)-9.81
Earnings DateAug 7, 2018 - Aug 13, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est193.92
Trade prices are not sourced from all markets
  • 6 Stocks Beating the Market
    GuruFocus.com3 days ago

    6 Stocks Beating the Market

    According to the GuruFocus All-in-One Guru Screener, the following stocks have outperformed the Standard & Poor's 500 index over the past 12 months and were bought by gurus during the third quarter. Warning! GuruFocus has detected 6 Warning Signs with BGNE. The share price is 50.86% above its 52-week low and 34.65% below its 52-week high.

  • Reuters6 days ago

    BRIEF-Beigene Receives U.S. FDA Breakthrough Therapy Designation For Zanubrutinib

    Jan 15 (Reuters) - Beigene Ltd: * RECEIVES U.S. FDA BREAKTHROUGH THERAPY DESIGNATION FOR ZANUBRUTINIB IN MANTLE CELL LYMPHOMA Source text for Eikon: Further company coverage:

  • MarketWatch6 days ago

    BeiGene drug gets 'breakthrough therapy' designation from FDA

    U.S. shares of BeiGene Ltd. rose in the extended session Monday after the biotech drug developer said the Food and Drug Administration will expedite the regulatory process for one of its drugs. BeiGene ADRs rose 4% after hours, following a 4.6% decline to close at $137.55 Monday. The company said the FDA gave a "Breakthrough Therapy" designation to its mantle cell lymphoma treatment, meaning the experimental drug zanubrutinib will get expedited review and guidance from the agency.

  • GlobeNewswire6 days ago

    BeiGene Receives U.S. FDA Breakthrough Therapy Designation for Zanubrutinib in Mantle Cell Lymphoma

    HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for its investigational Bruton’s tyrosine kinase (BTK) inhibitor, zanubrutinib, for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.

  • Barrons.com9 days ago

    Engaged Capital Helps Rethink Benchmark Electronics

    The goal is to turn the manufacturer into a designer, developer, and value-added partner. Plus, news on 10 other investors’ filings.

  • Reuters17 days ago

    BRIEF-Hillhouse Capital Management Ltd Reports 1.7 Pct Stake In Beigene Ltd

    Jan 3 (Reuters) - Beigene Ltd: * HILLHOUSE CAPITAL MANAGEMENT, LTD. REPORTS 1.7 PERCENT STAKE IN BEIGENE LTD AS OF JANUARY 1 - SEC FILING * HILLHOUSE CAPITAL MANAGEMENT, LTD. PREVIOUSLY REPORTED 9.29 PERCENT ...

  • Here's Why BeiGene Is Taking a Hit Today
    Motley Fool17 days ago

    Here's Why BeiGene Is Taking a Hit Today

    Shares tumble in response to an industry megamerger.

  • GlobeNewswire17 days ago

    BeiGene Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer, today announced that on December 31, 2018, the Compensation Committee of BeiGene’s Board of Directors granted restricted share units for an aggregate of 44,910 American Depositary Shares to 123 new employees under BeiGene’s Amended and Restated 2018 Inducement Equity Plan. The Amended and Restated 2018 Inducement Equity Plan is used exclusively for the grant of equity awards to individuals who were not previously employed by BeiGene or one of its subsidiaries as an inducement material to such individual's entering into employment with BeiGene or one of its subsidiaries, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules.

  • Do Analysts See Any Upside in BeiGene Stock?
    Market Realist23 days ago

    Do Analysts See Any Upside in BeiGene Stock?

    Of the 11 analysts covering BeiGene (BGNE), four have given it “strong buys,” and seven have given it “buys.” 

  • Understanding BeiGene’s Operational Performance
    Market Realist23 days ago

    Understanding BeiGene’s Operational Performance

    In its most recent quarter, BeiGene’s (BGNE) selling, general, and administrative expenses rose YoY (year-over-year) to $48.82 million from $15.64 million primarily due to an increased head count.

  • Taking Stock of BeiGene’s Latest Performance
    Market Realist23 days ago

    Taking Stock of BeiGene’s Latest Performance

    BeiGene Limited (BGNE) is a biopharmaceutical company with a focus on bringing to market molecularly targeted and immuno-oncology drugs for the treatment of cancer. In this series, we’ll explore BeiGene’s financials, valuation, and analyst views.

  • Assessing BeiGene Limited’s Gross Margin Trend
    Market Realist23 days ago

    Assessing BeiGene Limited’s Gross Margin Trend

    In the third quarter, BeiGene’s (BGNE) total revenue fell YoY (year-over-year) to $54.2 million from $220.21 million. During the quarter, it generated $10.24 million from the US market and $43.96 million from outside the United States. During the comparable period in 2017, it generated $137.4 million from the US market and $82.81 million from outside the United States.

  • Motley Fool27 days ago

    Don't Miss Chinese Biotechs

    It's not for the faint of heart, but it's hard to oversell just how huge the runway is for the Chinese biotech industry.

  • Motley Foollast month

    Our Top Stock Idea in China’s Biotech Revolution

    Whether you're in the U.S. or China, immuno-oncology is one of the hottest areas in biotech right now.

  • Has BeiGene, Ltd. (NASDAQ:BGNE) Got Enough Cash?
    Simply Wall St.last month

    Has BeiGene, Ltd. (NASDAQ:BGNE) Got Enough Cash?

    Stocks with market capitalization between $2B and $10B, such as BeiGene, Ltd. (NASDAQ:BGNE) with a size of US$7.9b, do not attract as much attention from the investing community as do Read More...

  • Reuterslast month

    BRIEF-Beigene Initiates Two Global Phase 3 Front-Line Clinical Trials Of Tislelizumab

    Dec 17 (Reuters) - Beigene Ltd: * BEIGENE INITIATES TWO GLOBAL PHASE 3 FRONT-LINE CLINICAL TRIALS OF TISLELIZUMAB, IN PATIENTS WITH GASTRIC CANCER AND IN PATIENTS WITH ESOPHAGEAL CANCER Source text for ...

  • GlobeNewswirelast month

    BeiGene Initiates Two Global Phase 3 Front-Line Clinical Trials of Tislelizumab, in Patients with Gastric Cancer and in Patients with Esophageal Cancer

    HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that the first patients have been enrolled in two global Phase 3 clinical trials of its investigational anti-PD-1 antibody, tislelizumab. “Available data have shown promise for anti-PD-1 antibodies in patients with advanced gastric or gastroesophageal adenocarcinoma and in patients with advanced esophageal carcinoma.

  • GlobeNewswirelast month

    BeiGene Announces Updated Phase 1A/1B Data on Tislelizumab Presented at the European Society for Medical Oncology Immuno-Oncology Congress

    HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, announced that updated clinical data from an ongoing Phase 1A/1B trial of tislelizumab, an investigational anti-PD-1 antibody, were presented in an oral session and a poster at the European Society for Medical Oncology Immuno-Oncology (ESMO-IO) Congress, being held December 13-16 in Geneva, Switzerland. “We continue to be pleased with the results of tislelizumab in solid tumors,” commented Amy Peterson, M.D., Chief Medical Officer, Immuno-Oncology, at BeiGene.

  • Is BeiGene, Ltd. (BGNE) Going to Burn These Hedge Funds?
    Insider Monkeylast month

    Is BeiGene, Ltd. (BGNE) Going to Burn These Hedge Funds?

    Hedge funds and other investment firms run by legendary investors like Israel Englander and Ray Dalio are entrusted to manage billions of dollars of accredited investors’ money because they are without peer in the resources they use to identify the best investments for their chosen investment horizon. Moreover, they are more willing to invest a […]

  • Here's Why BeiGene Stock Rose 21.7% in November
    Motley Foollast month

    Here's Why BeiGene Stock Rose 21.7% in November

    A third-quarter report and a couple of priority reviews from the China Food and Drug Administration encouraged investors.

  • GlobeNewswire2 months ago

    BeiGene Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer, today announced that on November 30, 2018, the Compensation Committee of BeiGene’s Board of Directors granted restricted share units for an aggregate of 46,689 American Depositary Shares to 144 new employees under BeiGene’s Amended and Restated 2018 Inducement Equity Plan. The Amended and Restated 2018 Inducement Equity Plan is used exclusively for the grant of equity awards to individuals who were not previously employed by BeiGene or one of its subsidiaries as an inducement material to such individual's entering into employment with BeiGene or one of its subsidiaries, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules.

  • GlobeNewswire2 months ago

    BeiGene Presents Clinical Results of Tislelizumab in Relapsed/Refractory Classical Hodgkin’s Lymphoma at the 60th American Society of Hematology Annual Meeting

    HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced the presentation of clinical data from the pivotal Phase 2 trial of its investigational anti-PD-1 antibody, tislelizumab, in Chinese patients with relapsed/refractory (R/R) classical Hodgkin’s lymphoma (cHL). “We set out to address the needs of patients with R/R cHL who have failed to achieve a response or progressed after autologous stem cell transplant (ASCT), or who are not candidates for ASCT, as these patients, unfortunately, have very poor outcomes,” said Jane Huang, M.D., Chief Medical Officer, Hematology, at BeiGene.

  • GlobeNewswire2 months ago

    BeiGene Announces Clinical Results of Zanubrutinib in Mantle Cell Lymphoma From Two Presentations at the 60th American Society of Hematology Annual Meeting

    CAMBRIDGE, Mass. and BEIJING, China, Dec. 01, 2018 -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and.

  • Chinese biotech stocks hit by a double whammy, which means it’s time to buy
    MarketWatch2 months ago

    Chinese biotech stocks hit by a double whammy, which means it’s time to buy

    The decline in biotech stocks is more about investors fleeing a high-beta group in a risk-off environment.